Form 4: Agios Pharmaceuticals Director Converts Restricted Stock Units to Common Shares

Jeffrey D. Capello, a Director at Agios Pharmaceuticals, Inc., converted 1,977 restricted stock units into common stock on June 13, 2025, as part of a routine vesting schedule.

Summary

• Jeffrey D. Capello, a Director of Agios Pharmaceuticals, Inc. (AGIO), converted 1,977 Restricted Stock Units (RSUs) into an equal number of common shares.
• This transaction occurred on June 13, 2025, and is categorized as an exercise or conversion of a derivative security.
• Following this conversion, Mr. Capello directly holds 3,953 shares of common stock.
• Additionally, he directly holds 1,976 remaining Restricted Stock Units.
• The RSUs were originally granted on June 13, 2023, and are scheduled to vest in three equal annual installments starting from June 13, 2024.

Sentiment

Score: 5

Explanation: The document is a neutral, factual disclosure of an insider transaction (RSU vesting and conversion), which is a routine event and does not inherently indicate positive or negative sentiment regarding the company's performance or outlook.

Positives

• The transaction demonstrates continued equity ownership by a director, aligning their interests with shareholders.
• It represents a routine and expected vesting event as part of the director's compensation plan.

Future Outlook

The document indicates that the remaining restricted stock units will continue to vest in equal annual installments.

Industry Context

This Form 4 filing is a standard disclosure of an insider equity transaction and does not provide broader industry context or trends. It reflects a common practice of equity-based compensation for corporate directors.

Related Party Transactions

• The conversion of restricted stock units into common stock by Jeffrey D. Capello, a Director of Agios Pharmaceuticals, Inc., constitutes a related party transaction as it involves an equity transaction between the company and a member of its board of directors.

Stakeholder Impact

• Shareholders: Provides transparency regarding director equity ownership and compensation, indicating alignment of interests through stock ownership.
• Employees: No direct impact mentioned, but reflects standard equity compensation practices.

Next Steps

• Remaining restricted stock units will continue to vest in equal annual installments.

Key Dates

Keywords

Agios Pharmaceuticals, AGIO, SEC Form 4, Insider Transaction, Restricted Stock Units, RSU Conversion, Director Stock Ownership, Equity Compensation, Stock Vesting